The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders
RANDI, MARIA LUIGIA;GIROLAMI, ANTONIO;FABRIS, FABRIZIO
2005
Abstract
The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
HU haem safety.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Accesso libero
Dimensione
150.28 kB
Formato
Adobe PDF
|
150.28 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
